日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bisphosphate nucleotidase 1 promotes progression and docetaxel resistance in triple-negative breast cancer via STUB1-mediated destabilization of LIMA1

双磷酸核苷酸酶 1 通过 STUB1 介导的 LIMA1 不稳定化促进三阴性乳腺癌的进展和多西他赛耐药性。

Ling, Yun-Xiao; Andriani, Lisa; Yang, Shao-Ying; Zhao, Qian; Huang, Min-Ying; Zhang, Yin-Ling; Zhang, Fang-Lin; Shao, Zhi-Min; Li, Da-Qiang; Liu, Guang-Yu

MYC/TET3-Regulated TMEM65 Activates OXPHOS-SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple-Negative Breast Cancer.

MYC/TET3 调控的 TMEM65 激活 OXPHOS-SERPINB3 通路,促进三阴性乳腺癌的进展和顺铂耐药性。

Zhang Yin-Ling, Huang Min-Ying, Yang Shao-Ying, Cai Jia-Yang, Zhao Qian, Zhang Fang-Lin, Hu Xin, Shao Zhi-Min, Liao Li, Cao A-Yong, Li Da-Qiang

Secernin-2 Stabilizes Histone Methyltransferase KMT2C to Suppress Progression and Confer Therapeutic Sensitivity to PARP Inhibition in Triple-Negative Breast Cancer.

Secernin-2 可稳定组蛋白甲基转移酶 KMT2C,从而抑制三阴性乳腺癌的进展并赋予其对 PARP 抑制剂的治疗敏感性

Huang Min-Ying, Cai Jia-Yang, Yang Shao-Ying, Zhao Qian, Shao Zhi-Min, Zhang Fang-Lin, Zhang Yin-Ling, Cao A-Yong, Li Da-Qiang

Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancer.

驱动蛋白样蛋白 KIFC2 可稳定 CDK4,从而加速 HR+/HER2- 乳腺癌的生长并赋予其耐药性

Yang Shao-Ying, Jin Ming-Liang, Andriani Lisa, Zhao Qian, Ling Yun-Xiao, Lin Cai-Jin, Huang Min-Ying, Cai Jia-Yang, Zhang Yin-Ling, Hu Xin, Shao Zhi-Ming, Zhang Fang-Lin, Jin Xi, Cao A Yong, Li Da-Qiang

Different exercise interventions on quality of sleep in breast cancer survivors-a network meta-analysis of randomized controlled trials

不同运动干预措施对乳腺癌幸存者睡眠质量的影响——一项随机对照试验的网络荟萃分析

Song, Qi; Zhu, You-Kang; Liu, Hai; Liu, Xiao; Jiang, Zhang-Dong; Wang, Yu-Jia; Xue, Li-Yun; Yang, Shao-Ying; Liu, Xi-Fang

C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer

C9orf142通过转录激活MTBP,驱动三阴性乳腺癌的进展并使其对CDK4/6抑制剂产生耐药性。

Liao, Li; Deng, Ling; Zhang, Yin-Ling; Yang, Shao-Ying; Andriani, Lisa; Hu, Shu-Yuan; Zhang, Fang-Lin; Shao, Zhi-Min; Li, Da-Qiang

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer

KLF5 促进卵巢癌肿瘤进展和 Parp 抑制剂耐药性

Yong Wu, Siyu Chen, Yang Shao, Ying Su, Qin Li, Jiangchun Wu, Jun Zhu, Hao Wen, Yan Huang, Zhong Zheng, Xiaojun Chen, Xingzhu Ju, Shenglin Huang, Xiaohua Wu, Zhixiang Hu

HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression

HSP90 N 端抑制剂靶向癌蛋白 MORC2 进行自噬降解并抑制 MORC2 驱动的乳腺癌进展

Fan Yang, Rui Sun, Zeng Hou, Fang-Lin Zhang, Yi Xiao, Yun-Song Yang, Shao-Ying Yang, Yi-Fan Xie, Ying-Ying Liu, Cheng Luo, Guang-Yu Liu, Zhi-Min Shao, Da-Qiang Li

Compelling Evidence Linking CD40 Gene With Graves' Disease in the Chinese Han Population

强有力的证据表明CD40基因与中国汉族人群的格雷夫斯病有关

Jiang, He; Yuan, Fei-Fei; Wang, Hai-Ning; Liu, Wei; Ye, Xiao-Ping; Yang, Shao-Ying; Xie, Hui-Jun; Yu, Sha-Sha; Ma, Yu-Ru; Zhang, Le-Le; Zhao, Shuang-Xia; Song, Huai-Dong

Assessment of Molecular Subtypes in Thyrotoxic Periodic Paralysis and Graves Disease Among Chinese Han Adults: A Population-Based Genome-Wide Association Study

中国汉族成年人甲状腺毒性周期性麻痹和格雷夫斯病分子亚型的评估:一项基于人群的全基因组关联研究

Zhao, Shuang-Xia; Liu, Wei; Liang, Jun; Gao, Guan-Qi; Zhang, Xiao-Mei; Yao, Yu; Wang, Hai-Ning; Yuan, Fei-Fei; Xue, Li-Qiong; Ma, Yu-Ru; Zhang, Le-Le; Ye, Xiao-Ping; Zhang, Qian-Yue; Sun, Feng; Zhang, Rui-Jia; Yang, Shao-Ying; Zhan, Ming; Du, Wen-Hua; Liu, Bing-Li; Chen, Xia; Song, Zhi-Yi; Li, Xue-Song; Li, Ping; Ru, Ying; Zuo, Chun-Lin; Li, Sheng-Xian; Han, Bing; Zhu, Hui; Qiao, Jie; Xuan, Miao; Su, Bin; Sun, Fei; Ma, Jun-Hua; Chen, Jia-Lun; Tian, Hao-Ming; Chen, Sai-Juan; Song, Huai-Dong